fentaNYL 1250 mcg/250 mL (5 mcg/mL) in 0.9% Sodium Chloride 250 mL Bag Preservative Free, Rx, QuVA Pharma 1075 West Park One Drive, Suite 100 Sugar Land, TX 77478 NDC 70092-1444-05
Published December 11, 2019 · Recall initiated: November 12, 2019
Summary
FDA records drug Class II recall D-0567-2020, published December 11, 2019 and initiated November 12, 2019. Recalling firm: QuVa Pharma, Inc.; Status: Terminated; Lot: Lots: 10029186 Exp. 11/18/2019, 10029791 Exp. 11/18/2019, 10030403 Exp. 11/25/2019, 10030456 Exp. 11/27/2019, 10030910 Exp. 12/2/2019, 10030403 Exp. 11/25/2019, 10031154 Exp. 12/8/2019, 10031238 Exp. 12/10/2019, 10031182 Exp. 12/9/2019, 10031130 Exp. 12/8/2019, 10031483 Exp. 12/16/2019, 10031482 Exp. 12/16/2019, 10031621 Exp. 12/19/2019, 10031592 Exp. 12/19/2019, 10031921 Exp. 12/25/2019, 10031869 Exp. 12/24/2019, 10032219 Exp. 12/29/2019, 10032393 Exp. 1/1/2020, 10032369 Exp. 1/1/2020, 10032561 Exp. 1/6/2020, 10032586 Exp. 1/6/2020, 10031898 Exp. 12/26/2019. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.
Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.
What's the hazard
Presence of Particulate matter: manufacturer recalled fentanyl API due to potential for glass particules
What to do
Voluntary: Firm initiated · Letter
Get an email when a new FDA recall like this is published
Free. We only write when there's a new recall that matches. Unsubscribe in one click.
Recall details
- Manufacturer
- QuVa Pharma, Inc.
- Distributor
- Nationwide.
- Lot
- Lots: 10029186 Exp. 11/18/2019, 10029791 Exp. 11/18/2019, 10030403 Exp. 11/25/2019, 10030456 Exp. 11/27/2019, 10030910 Exp. 12/2/2019, 10030403 Exp. 11/25/2019, 10031154 Exp. 12/8/2019, 10031238 Exp. 12/10/2019, 10031182 Exp. 12/9/2019, 10031130 Exp. 12/8/2019, 10031483 Exp. 12/16/2019, 10031482 Exp. 12/16/2019, 10031621 Exp. 12/19/2019, 10031592 Exp. 12/19/2019, 10031921 Exp. 12/25/2019, 10031869 Exp. 12/24/2019, 10032219 Exp. 12/29/2019, 10032393 Exp. 1/1/2020, 10032369 Exp. 1/1/2020, 10032561 Exp. 1/6/2020, 10032586 Exp. 1/6/2020, 10031898 Exp. 12/26/2019
- Risk classification
- Class II
- Area (FDA)
- drug
- Country
- United States
Related recalls
- FDAMethohexital Sodium, 100 mg/10 mL (10 mg/mL), Total Volume: 10 mL, Rx only, Compounded drug, QuVa Pharma, 1075July 15, 2026
- FDAR.E.C.K. (Ropivacaine HCl, EPINEPHrine, CloNIDine HCl, and Ketorolac Tromethamine) in Sodium ChlorideNovember 5, 2025
- FDAfentaNYL Citrate PF 200 mcg/100 mL (2 mcg/ml) /0.125% Bupivacaine HCl 125 mg/100 mL (1.25 mg/mL), 100 ml in NSApril 2, 2025
- FDAfentaNYL Citrate PF 200 mcg/100 mL (2 mcg/ml) /0.1% Bupivacaine HCl 100 mg/100 mL (1 mg/mL), 100 ml in NSApril 2, 2025
- FDAfentaNYL 200 mcg/100 mL (2 mcg/mL) BUPivacaine HCl 0.1% 100 mg/100 mL (1 mg/mL) in 0.9% Sodium ChlorideDecember 11, 2019
- FDAfentaNYL 800 mcg/200 mL (4 mcg/mL) BUPivacaine HCl 0.1667% 333.4 mg/200 mL (1.667 mg/mL) in 0.9% SodiumDecember 11, 2019
Questions about this recall
Was fentaNYL 1250 mcg/250 mL (5 mcg/mL) in 0.9% Sodium Chloride 250 mL Bag Preservative Free, Rx, QuVA Pharma 1075 West Park One Drive, Suite 100 Sugar Land, TX 77478 NDC 70092-1444-05 recalled?
Yes. FDA published recall D-0567-2020 on December 11, 2019. Reported hazard: Presence of Particulate matter: manufacturer recalled fentanyl API due to potential for glass particules
What should I do if I have this product?
Voluntary: Firm initiated · Letter